Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer.

Biomarker Gastric cancer Hemoglobin, albumin, lymphocyte, and platelet score Nutritional index Prognosis Survival

Journal

World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470

Informations de publication

Date de publication:
15 Sep 2023
Historique:
received: 26 04 2023
revised: 17 06 2023
accepted: 29 07 2023
medline: 25 9 2023
pubmed: 25 9 2023
entrez: 25 9 2023
Statut: ppublish

Résumé

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies. To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer. The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were determined using receiver operating characteristic analysis. Low HALP scores were defined as those less than 24.79 and high HALP scores as those greater than 24.79. The study cohort comprised 147 patients and 110 of them (74.8%) were male. The patients' median age was 63 (22-89) years. The median overall survival was significantly superior in the patients with high HALP scores than in those with low HALP scores (10.4 mo The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.

Sections du résumé

BACKGROUND BACKGROUND
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies.
AIM OBJECTIVE
To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer.
METHODS METHODS
The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were determined using receiver operating characteristic analysis. Low HALP scores were defined as those less than 24.79 and high HALP scores as those greater than 24.79.
RESULTS RESULTS
The study cohort comprised 147 patients and 110 of them (74.8%) were male. The patients' median age was 63 (22-89) years. The median overall survival was significantly superior in the patients with high HALP scores than in those with low HALP scores (10.4 mo
CONCLUSION CONCLUSIONS
The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.

Identifiants

pubmed: 37746652
doi: 10.4251/wjgo.v15.i9.1626
pmc: PMC10514725
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1626-1635

Informations de copyright

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors declare no conflict of interest.

Références

Mol Cell Pediatr. 2018 Apr 3;5(1):5
pubmed: 29616417
Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42-54
pubmed: 31648970
Gastric Cancer. 2017 Mar;20(2):217-225
pubmed: 26897166
Am J Med. 2004 Apr 5;116 Suppl 7A:11S-26S
pubmed: 15050883
Oncotarget. 2015 Dec 1;6(38):41370-82
pubmed: 26497995
World J Surg. 2010 Oct;34(10):2393-8
pubmed: 20602101
J Gastrointest Cancer. 2019 Dec;50(4):763-768
pubmed: 30058031
Int J Clin Exp Med. 2015 Apr 15;8(4):5937-42
pubmed: 26131188
Ann Surg. 2005 Jan;241(1):27-39
pubmed: 15621988
Oncotarget. 2016 Nov 1;7(44):72076-72083
pubmed: 27765916
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
Anticancer Res. 2008 May-Jun;28(3B):1947-50
pubmed: 18630486
Front Oncol. 2022 Aug 30;12:936206
pubmed: 36110962
Sci Rep. 2018 Jan 15;8(1):794
pubmed: 29335609
J Gastrointest Oncol. 2021 Dec;12(6):2706-2718
pubmed: 35070400
J Coll Physicians Surg Pak. 2022 Sep;32(9):1154-1159
pubmed: 36089712
Oncol Lett. 2016 May;11(5):2959-2964
pubmed: 27123046
World J Surg Oncol. 2020 Jul 30;18(1):191
pubmed: 32731872

Auteurs

Yakup Duzkopru (Y)

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.

Abdulkadir Kocanoglu (A)

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.

Ozlem Dogan (O)

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.

Hayriye Sahinli (H)

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.

Ebru Cilbir (E)

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.

Mustafa Altinbas (M)

Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.

Classifications MeSH